Beam Therapeutics Inc.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
BEAM$25.15-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating activities | ||
| Net loss | $(94,318) | $(108,330) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | ||
| Depreciation and amortization | 5,605 | 5,528 |
| Amortization of investment discount (premiums) | (2,763) | (3,849) |
| Amortization of debt discount | 35 | — |
| Stock-based compensation expense | 19,044 | 26,682 |
| Change in operating lease right-of-use assets | 2,532 | 2,649 |
| Change in fair value of derivative liabilities | (2,500) | (3,200) |
| Change in fair value of contingent consideration liabilities | (514) | 27 |
| Change in fair value of non-controlling equity investments | (16) | 2,081 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (31,861) | 49 |
| Accounts payable | 2,216 | 3,793 |
| Accrued expenses and other liabilities | (16,258) | (18,458) |
| Operating lease liabilities | (3,494) | (3,297) |
| Deferred revenue | (6,355) | (7,470) |
| Other long-term liabilities | 134 | (89) |
| Net cash provided by (used in) operating activities | (128,513) | (103,884) |
| Investing activities | ||
| Purchases of property and equipment | (2,232) | (3,065) |
| Purchases of marketable securities | (153,792) | (339,169) |
| Maturities of marketable securities | 181,293 | 217,145 |
| Net cash provided by (used in) investing activities | 25,269 | (125,089) |
| Financing activities | ||
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | — | 471,159 |
| Proceeds from issuances of stock under ESPP | 1,510 | 1,501 |
| Proceeds from exercise of stock options | 2,025 | 719 |
| Proceeds from the issuance of debt, net of fees paid to lender | 93,886 | — |
| Payments of debt issuance costs | (813) | — |
| Net cash provided by (used in) financing activities | 96,608 | 473,379 |
| Net change in cash, cash equivalents and restricted cash | (6,636) | 244,406 |
| Cash, cash equivalents and restricted cash—beginning of period | 301,620 | 290,111 |
| Cash, cash equivalents and restricted cash—end of period | $294,984 | $534,517 |
Condensed Consolidated Statements of Cash Flows - Continued
(in thousands)
| Three Months Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Supplemental disclosure of noncash investing and financing activities: | ||
| Property and equipment additions in accounts payable and accrued expenses | $1,391 | $1,455 |
| Equity issuance costs in accounts payable and accrued expenses | $— | $641 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.